Mason Street Advisors LLC Purchases New Position in Supernus Pharmaceuticals Inc. (SUPN)
Mason Street Advisors LLC purchased a new stake in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) during the second quarter, Holdings Channel reports. The firm purchased 6,763 shares of the specialty pharmaceutical company’s stock, valued at approximately $138,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. TIAA CREF Investment Management LLC raised its position in Supernus Pharmaceuticals by 37.0% in the first quarter. TIAA CREF Investment Management LLC now owns 190,959 shares of the specialty pharmaceutical company’s stock worth $2,912,000 after buying an additional 51,580 shares in the last quarter. Teachers Advisors Inc. raised its position in Supernus Pharmaceuticals by 9.1% in the first quarter. Teachers Advisors Inc. now owns 550,195 shares of the specialty pharmaceutical company’s stock worth $8,390,000 after buying an additional 46,100 shares in the last quarter. BlackRock Fund Advisors raised its position in Supernus Pharmaceuticals by 1.1% in the first quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock worth $43,112,000 after buying an additional 31,238 shares in the last quarter. Nicholas Investment Partners LP bought a new position in Supernus Pharmaceuticals during the first quarter worth $1,990,000. Finally, Granahan Investment Management Inc. MA bought a new position in Supernus Pharmaceuticals during the first quarter worth $5,945,000. Institutional investors and hedge funds own 94.62% of the company’s stock.
Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) opened at 20.81 on Monday. The company’s 50 day moving average price is $23.57 and its 200-day moving average price is $20.29. The stock has a market capitalization of $1.03 billion, a P/E ratio of 42.47 and a beta of 1.73. Supernus Pharmaceuticals Inc. has a 12 month low of $9.51 and a 12 month high of $26.84.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The company had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. During the same quarter in the previous year, the business earned $0.03 EPS. Supernus Pharmaceuticals’s revenue was up 43.6% compared to the same quarter last year. Equities analysts predict that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current year.
A number of research firms have recently weighed in on SUPN. Jefferies Group set a $28.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Wednesday, October 5th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a report on Monday, July 18th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $25.25.
In related news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares in the company, valued at approximately $90,400. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.10% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.